Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
50,580,036
-
Total 13F shares
-
36,983,052
-
Share change
-
-32,292
-
Total reported value
-
$453,043,903
-
Put/Call ratio
-
42%
-
Price per share
-
$12.25
-
Number of holders
-
92
-
Value change
-
+$5,790,575
-
Number of buys
-
53
-
Number of sells
-
44
Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q4 2023
As of 31 Dec 2023,
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) was held by
92 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
36,983,052 shares.
The largest 10 holders included
VR Adviser, LLC, Frazier Life Sciences Management, L.P., TANG CAPITAL MANAGEMENT LLC, TCG Crossover Management, LLC, SUVRETTA CAPITAL MANAGEMENT, LLC, BlackRock Inc., Saturn V Capital Management LP, VANGUARD GROUP INC, Boxer Capital, LLC, and Jefferies Financial Group Inc..
This page lists
92
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.